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Background
Colorectal cancer (CRC) is one of the most common malignancies in the world, accounting for approximately 1.36 million new cases worldwide every year [1] .
Although advances in detection and local control with surgery, radiation and chemotherapy, the overall survival rate of colorectal cancer patients has not improved significantly during the past several decades. Chemotherapy is a common therapeutic strategy after surgery, and the marketed chemotherapy drugs kill tumour cells through competitive inhibition of nucleotide synthesis or cytotoxicity. However, these drugs often cause vomiting, myelosuppression, drug resistance and other adverse effects [2] . Therefore, searching for novel anticancer components of traditional Chinese medicine has become a very interesting option for developing anti-colorectal cancer drugs.
Shikonin, a natural occurring naphthoquinone, has potent anti-tumour activity.
Shikonin is able to inhibit cell proliferation and induces apoptosis in several human malignancies such as gastric cancer [3] , non-small cell lung cancer [4] , pancreatic cancer [5] and so on. However, certain limitations exist, including no clear target and liver and kidney toxicity [6] . Therefore, highly anti-cancer and low or even nontoxic shikonin-like compounds cause our concerns. Shikonin derivatives have exhibited antivirus, antioxidation, anti-inflammatory, anti-fertility, and other pharmacological effects in previous studies [7] . Additionally, shikonin derivatives have strong anti-tumour activities with few adverse effects, which make shikonin derivatives as promising anti-tumour agents [8] .
In this study, Acetylshikonin as a major chemical component was extracted and isolated from the dried roots of Arnebia euchroma by preparing HPLC.
Acetylshikonin, as one of shikonin derivatives, has been shown to possess anticancer activity [9] [10] with less toxicity [6] . However, the potential activity and underlying mechanism of Acetylshikonin in colorectal cancer inhibition remain unknown. In our study, we examined the anticancer activity of Acetylshikonin in human colorectal cancer cells in vitro and in human colorectal cancer xenografts NOD/SCID mice in vivo. These new results provided a framework for further exploration of Acetylshikonin which possessed the potential antitumor activity by inhibiting PI3K/Akt/mTOR pathway.
Methods

General
Optical rotations were measured using a JASCO P-1030 (Tokyo, Japan) automatic digital polarimeter. NMR spectra were recorded on a Bruker DPX-400 spectrometer (400 MHz for 1 H NMR and 100 MHz for 13 C NMR, Karlsruhe, Germany) using standard Bruker pulse programs. Chemical shifts were showed as the δ-value with reference to tetramethylsilane (TMS) as an internal standard. 
Extraction and Isolation
The roots of A. euchroma were purchased in Haozhou, Anhui Province, China, and subjected to taxonomic identification with Voucher specimens (No. 161001) deposited at Center Lab of Longhua Branch, Shenzhen People's Hospital, 2nd
Clinical Medical College of Jinan University in Shenzhen, China. The roots of A. euchroma (7.5 13 C NMR (CDCl 3 , 100 MHz) data: 178.1 (C-1), 148.2 (C-2), 136.1 (C-3), 176.6 (C-4), 111.6 (C-5), 169.7 (C-6), 131.5 (C-7), 132.7 (C-8), 167.0 (C-9), 111.8 (C-10), 69.5 (C-1'), 32.8 (C-2'), 117.6 (C-3'), 132.9 (C-4'), 17.9 (C-5'), 25.7 (C-6'), 167.6 (C-1''), 20.9 (C-2").
Cell Culture
Four human colon carcinoma cell lines including HT29, DLD-1, HCT116, Caco-2 were cultured in the Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 100 μg/ml penicillin, and 100 μg/mL streptomycin. The cells were incubated at 37˚C in a humidified atmosphere with 5% CO 2 .
Methyl Thiazolyl Tetrazolium (MTT) Assay
HT29 cells (5 × 10
3 cells/well) were seeded in 96-well plates and cultured for 24
h. Cells were treated with various concentrations of Acetylshikonin (6.25, 12.5, 25, 50, 100 μg/mL) for 24 or 48 h. 20 μl MTT solution (0.5 mg/mL in PBS) was supplemented into each well and incubated for an additional 4 hours. The supernatant was then discarded, and 100 μL DMSO was added to dissolve the formazan crystals. Optical density was read at a wavelength of 490 nm on a microplate reader. Cytotoxicity of Acetylshikonin was assessed as described previously, and calculated by the following formula:
Cell Proliferation Assay
Cell proliferation analysis was conducted using the Cell Counting Kit-8 (CCK-8) 
Cell Cycle Analysis Assay
Real-Time Polymerase Chain Reaction (RT-PCR)
HT29 cells were treated with Acetylshikonin at different concentration of 0, 25, 50, 100 μg/ml for 48 h. Total RNA was extracted by Omega total RNA extraction kit and the total RNA was reverse transcribed using TaKaRa 
Hematoxylin/Eosin (H & E) Staining
Tumours were collected, fixed in formalin and embedded in paraffin. Tissue sections (5 μm in thickness) were prepared according to standard protocols for H&E staining. After staining, the tissue slices were viewed under microscopy with the Olympus DP controller software program (Tokyo, Japan).
Statistical Analysis
All experiments were performed at least three times, independently. The results were analysed using GraphPad Prism version 6.0 to perform one-way ANOVA.
P value less than 0.05 was considered statistically significant.
Results and Discussion
Isolation and Identification of Acetylshikonin
Acetylshikonin (Figure 1 ) was isolated from the extracts of A. euchroma by bioassay-guided fractionation, and identified using spectral analysis by 1 
Acetylshikonin Exhibited Anti-Proliferative Activity against Human Colorectal Cancer Cells
To explore the effects of Acetylshikonin on colorectal cancer cells proliferation, HT29 cells were exposed to different concentration of Acetylshikonin for 24 or 48 h, and cell viability was measured using the MTT assay. As shown in Figure   2 
Acetylshikonin Induced Apoptosis in HT29 Cells
Flow cytometry was performed to detect the apoptosis manner with Annexin V and PI staining. 
Acetylshikonin Induced Cell Cycle Arrested at G0/G1 in HT29 Cells
The effect of Acetylshikonin on regulation of the cell cycle in HT29 cells was studied using Cycletest Plus DNA Reagent kit, and the results were evaluated by flow cytometry. As shown in Figure 4 To further determine the relationship between cell apoptosis and activation of These results demonstrated that apoptosis is induced by Acetylshikonin in HT29 cells via PI3K/Akt/mTOR signaling pathway. Traditional Chinese medicine, envisioned as safer alternatives for their chemical counterparts, has been used for preventing cancer for centuries. Currently, effective components isolated from traditional Chinese medicines have become an important approach to discover anti-cancer drugs [13] .
Acetylshikonin Inhibited the Growth of Xenografted
In our study, Acetylshikonin was extracted and isolated from the dried roots Apoptosis is a genetically programmed process leading to cell death, which primarily functions to eliminate senescent or altered cells that are useless or harmful to health. In contrast, abnormal changes in apoptotic mechanisms that promote deficient programmed cell death are closely related to the occurrence and development of tumours [14] . Recent evidence has indicated that selective induction of apoptosis in tumour cells is the most direct and efficacy method to treat tumours [15] . In our study, to further clarify the inhibitory effects of Acetylshikonin on colorectal cancer, Annexin V/PI staining was applied to detect the effect of Acetylshikonin on HT29 cells apoptosis. The proportion of total apoptotic cells (particularly early apoptosis) induced by Acetylshikonin was significantly increased dose-dependently.
Cell cycle progression plays an important role in tumour growth, and its regulation is an effective strategy to control tumour growth. It has been reported that the active ingredients of traditional Chinese medicine can arrest tumour cells at different cell cycle, which in turn inhibit tumour cell growth, proliferation, and induce apoptosis [16] [17] . In present study, Acetylshikonin blocked cell cycle progression at G0/G1 phase, which demonstrated that Acetylshikonin interfered with the normal tumour cell cycle and inhibited tumour growth.
PI3K/Akt/mTOR pathway regulates multiple cellular processes such as growth [18] , proliferation [19] , cell cycle progression [20] , motility [18] , adhesion [21] , The expression of these proteins including PI3K, p-PI3K, Akt, p-Akt and mTOR in the tumour tissue of control, Acetylshikonin and irinotecan treatment groups were analysed by Western blot. Data are presented as mean ± SD. *P < 0.05, **P < 0.001, ***P < 0.0001, ****P < 0.00001 compared to the control group. and angiogenesis [22] . Previous studies have indicated that abnormal activation of PI3K/Akt/mTOR signaling pathway is commonly involved in the development and progression of various tumours [23] [24] [25] , especially colorectal cancer [26] . Akt is one of core target proteins to downstream of PI3K, which relies on the phosphorylation at the Thr308 site of the catalytic domain and the Ser473 site of the regulatory domain of the C-terminus. In this study, we found Acetylshikonin down-regulated Akt phosphorylation at Thr308. However, the precise molecular mechanism by which Acetylshikonin deactivates Akt should be further investigated. Combining Acetylshikonin with LY294002 largely increased the rate of cell inhibitory, early apoptosis and G0/G1 phase distribution of HT29. As a targeted anti-cancer drug LY294002, has also been reported in several cancers, Acetylshikonin may also be useful for improving anti-cancer activity of PI3K/Akt/mTOR-targeting drugs. 
Conclusions
In conclusion, our study demonstrated that Acetylshikonin possessed the anti-cancer activity in human colorectal cancer. Acetylshikonin effectively inhibited cell proliferation, induced cell cycle arrested at G0/G1 and promoted colorectal cancer cells apoptosis in vitro. Colorectal cancer growth was also suppressed by Acetylshikonin in vivo. Meanwhile, activation of PI3K/Akt/mTOR signaling pathway played a crucial role in the treatment with Acetylshikonin. Collectively, these findings reveal that Acetylshikonin may serve as an anti-tumour candidate for colorectal cancer treatment. 
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